Skip Navigation

Phase II Trial of Eflornithine/DFMO as Maintenance Therapy for Molecular High Risk/Very High Risk and Relapsed/Refractory Medulloblastoma

Brief Summary

Type:
Brain Tumors / Neurologic Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT04696029

Study #:
CMH - BCC016

Start Date:
Jun 27, 2021

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04696029

View Complete Trial Details & Eligibility at ClinicalTrials.gov